INMUNE BIO INC. - COMM

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

05 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

12 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

06 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

30 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

02 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

18 12 2023 15:01:00 提供 Nasdaq GlobeNewswire

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

29 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

27 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe

15 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

01 11 2023 15:10:41 提供 Nasdaq GlobeNewswire

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

31 10 2023 07:00:00 提供 Nasdaq GlobeNewswire

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα

30 10 2023 08:07:00 提供 Nasdaq GlobeNewswire

INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

17 10 2023 07:00:00 提供 Nasdaq GlobeNewswire

INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1

16 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference

07 9 2023 08:00:00 提供 Nasdaq GlobeNewswire

INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease

05 9 2023 07:00:01 提供 Nasdaq GlobeNewswire

INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update

07 8 2023 15:00:18 提供 Nasdaq GlobeNewswire

INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference

01 8 2023 07:00:01 提供 Nasdaq GlobeNewswire

INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7

31 7 2023 07:00:00 提供 Nasdaq GlobeNewswire

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.

12 7 2023 07:00:00 提供 Nasdaq GlobeNewswire